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Abstract: The imbalance between coagulation and fibrinolysis leads to vascular complications in diabetics. In our study, we have
investigated the effects of the protein C-thrombomodulin system as a cause of diabetic vascular complications.
Whereas PC-Ag levels were lower, thrombomodulin (TM) levels of diabetics were higher than that of the controls (P < 0.001, P <
0.001 respectively).
Furthermore, patients were divided into three groups according to their urinary albumin excretion (UAE). Group 1, 2 and 3 consisted
of 27 patients with UAC ≤ 30 µg/ml, 16 patients with UAC in range 30-140 µg/ml, 3 patients with UAC >140 µg/ml, respectively.
Plasma PC-Ag levels were significantly decreased in group 1 and 2 with respect to controls (P < 0.01, P < 0.01). Plasma TM
concentrations were significantly increased in group 1, 2 and 3 compared with the control group (P < 0.001, P < 0.01, P < 0.01).
Patients were also divided into two groups according to the duration of their illness; patients whose diabetic age < 10 years (Group
A) and whose diabetic age > 10 years (Group B). In both groups, PC-Ag levels were lower and TM levels higher than that of the
control group (P < 0.01, P < 0.01; P < 0.001, P < 0.001 respectively). There was no significant difference between group A and
B in PC-Ag levels (P > 0.50) but a significant difference in TM levels (P < 0.001).
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Introduction
Patients suffering from diabetes mellitus (DM) are at
increased risk of premature mortality and morbidity,
mostly through the development of atherothrombotic
vascular diseases. Vascular complications occur earlier and
more frequently than in non-diabetic subjects.
Abnormalities in the endothelium (1) and plasma
coagulation system (2-5) may contribute to premature
atherothrombotic diseases in DM. In this study we
investigated the protein C antigen (PC-Ag), protein C
activity (PCA) and thrombomodulin (TM) levels of
diabetic subjects.
TM plays an important role in the protein C
anticoagulant pathway which is initiated when thrombin
binds to TM, an integral membrane receptor found
primarily on the endothelium (6, 7). The
thrombomodulin-thrombin complex activates protein C

rapidly. Once activated, protein C binds to protein S and
inactivates either factor Va or factor VIIIa on the surface
of negatively charged phospholipids or on the membranes
of activated cells. The thrombin-thrombomodulin
complex is inhibited by either antithrombin or protein C
inhibitor (7). Increased plasma TM levels are related to
endothelial cell damage and disturbances of the organs
responsible for TM clearance (6).

Materials and Methods
We studied 46 patients with type II diabetes mellitus
and 24 healthy people recruited for the study (Table 1).
Patients with a history of acute ischemic heart
disease, cerebrovascular and peripheral vascular disease,
and liver or kidney function impairment were excluded
from the study.
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Table 1. Age, Glucose and HbA1c Levels of Patients and Controls.
Age
mean± SD
(min-max)

Glucose
mean± SD
(min-max)

HbA1c
mean± SD
(min-max)

Patients
(30 female and 16 male)

60.43± 12.02
(38-81)

173.2 ± 62.2
(72-357)

173.2 ± 62.2
(4.9-12.8)

Controls

59.44 ± 9.32

82.2 ± 8.4

5.2 ± 0.28

(45 - 84)

(70-106)

(4.8-5.8)

P > 0.50

P < 0.001

P < 0.001

(16 female and 8 male)

Activated partial thromboplastin time (APTT),
prothrombin time (PT), fibrinogen, TM, PC-Ag and PCA
measurements were performed in citrated plasma.
Hemoglobin A1C (HbA1C) measurement was performed on
heparinized whole blood. Liver enzymes (alanine
aminotransferase, aspartate aminotransferase, γglutamyltransferase), urea, uric acid, creatinine,
cholesterol and glucose levels were measured in serum on
the day of blood collection. We used the urine samples
which were collected over a 24-hour period for UAE
detection. Urine specimens contaminated with bacteria,
white blood cells or red blood cells were excluded.

lower than that of the control group but the difference
between both groups was not statistically significant (P >
0.05). Finally, with respect to healthy control subjects,
diabetic patients had significantly higher levels of TM
concentration (P < 0.001) (Table 2).

Plasma TM and PC-Ag were measured by enzyme
linked immunoabsorbent assay (ELISA) (Asserachrome
Thrombomodulin, and Asserachrome Protein C
respectively), Protein C activity measurements were made
by using Staclot Prot C (Diagnostica Stago). HbA1C was
measured by the immunologic method (Roche Diagnostic
HbA1C). We determined the urinary albumin excretion
(UAE) levels with the Orion Diagnostica Turbox UAlbumin
assay,
which
was
a
liquid-phase
immunoprecipitation assay with nephelometric end point
detection.

Group 1, 2, 3 had lower PC levels than that of the
control group. Although the differences between group
1, 2 and the control group were statistically significant (P
< 0.01, P < 0.01), the difference between group 3 and
the control group was not significant (P > 0.05) (Table
3).

We evaluated the statistical significance of the results
and the correlation between parameters by using T-test
and Pearson –Bravis Correlation coefficients, respectively.

These patients were allocated to three groups
according to their albumin excretions. Group 1 consisted
of 27 patients with UAE levels smaller than 30µg/ml,
group 2 consisted of 16 patients with UAE levels within
the range of 30- 140 µg/ml and group 3 consisted of 3
patients whose UAE levels were higher than 140 µg/ml.

Table 2. PC-Ag, PCA and Thrombomodulin Levels of Patients and
Controls.

Patients

PC-Ag (%)
Mean± SD

PCA (%)
Mean ± SD

TM (ng/ml)
Mean ± SD

66.28 ± 12.98

136.36 ± 49

34.37 ± 11.75

n = 46

n = 42

n = 46

78.38 ± 15.58

140.94 ± 32.1

25.55 ± 8.47

n = 24

n = 17

n = 24

< 0.001

> 0.05

< 0.001

Results
Control group

We measured PC- Ag, PCA and TM levels in both
patient and control groups. PC- Ag levels of patient group
were significantly lower than that of the control group (P
< 0.001). PCA levels of Type II diabetic patients were
306
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Table 3. PC-Ag, PCA and Thrombomodulin levels of group 1, 2, 3 and
control group.
PC-Ag (%)
Mean± SD

PCA (%)
Mean ± SD

TM (ng/ml)
Mean ± SD

Group I

66.74 ±12.77
n = 27
P1 < 0.01

141.4 ± 44,24
n = 23
P4 > 0.05

33.37 ± 13.43
n = 27
P7 < 0.001

Group II

64.13 ± 14.18
n = 16
P2 < 0.01

131.5 ± 57.22
n = 16
P5 > 0.05

34.92 ± 4.64
n = 16
P8 < 0.01

73.67 ± 6.66
n=3
P3 > 0.05

122.5 ± 50.65
n=3
P6 > 0.05

40.33 ± 4.64
n=3
P9 < 0.01

78.38 ± 15.588
n = 24

140.94 ± 32.1
n = 17

25.55 ± 8.47
n = 24

Group III

Control group

While PCA levels of group 1were higher, PCA levels of
group 2 and 3 were lower than that of the control group,
but the differences were not statistically significant (P >
0.05) (Table 3).
Plasma TM levels of group 1, 2 and 3 were higher
than the control groups (P < 0.001, P < 0.01, P < 0.01).
Although TM levels of the group 2 were also higher than
group 1, the difference between these two groups was
not statistically significant (Table 3).

The type II diabetic patients were classified into the
following sub-groups according to the duration of DM:
Group A consisted of 33 patients with a diabetes duration
shorter than 10 years and group B consisted of 9 patients
with a diabetes duration longer than 10 years. In both
patient groups TM levels were significantly higher than
that of the control group (P < 0.01 and P < 0.01,
respectively). Moreover the difference between group A
and B was also statistically significant (P < 0.01) (Table
4).
PC-Ag levels of Group A and B were significantly
lower than that of the control group (P < 0.001 and P <
0.001, respectively). The differences between PC–Ag
levels of Groups A and B were not significant (pAB> 0.50).
There were no significant differences between PCA levels
of Group A, and the control group (P > 0.50) and Group
B and the control group (P > 0.30). However the
differences between PCA levels of Group A and Group B
were significant (PAB<0.001) (Table 4).
There was a positive correlation between PC-Ag and
cholesterol levels in the patient group (r=+0.403, P <
0.001). We found that there was a weak negative
correlation between PC-Ag and glucose and aPTT
(r= -0.220 and –0.216 respectively). There were strong
correlations between PC- Ag and APC levels (r=+0.521,
P < 0.001). There were also a correlation between PCA
and cholesterol levels of the patient group (r=+0.402, P
< 0.001).

Table 4. Comparison of PC-Ag, PCA and Thrombomodulin levels of Groups A and B.
PC-Ag (%)
Mean± SD

PCA (%)
Mean ± SD

TM (ng/ml)
Mean ± SD

Group A (n= 33)

67.24 ± 12.64
P < 0,001

144 ± 40.03
P > 0,50

33.25 ± 11.18
P < 0,01

Group B (n= 9)

66.11 ± 15.34
P < 0,001

120.84 ± 64
P > 0,30

40.66 ± 6.83
P < 0,001

Control Group

78.38 ± 15.58
n = 24

140.94 ± 32.1
n = 17

25.55 ± 8.47
n = 24

PAB > 0.50

PAB <0.001

PAB <0.01

P value (comparison
of Group A and B)
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Discussion
The non-thrombogenic properties of endothelium are
very important for maintaining normal haemostatic
balance. Disturbances in this balance may lead to an
increase in thrombogenic tendencies or may trigger the
pathophysiologic mechanism which causes atherosclerotic
lesions (2). It is known that atherosclerosis and
atherosclerosis-related complications are the primary
cause of morbidity and premature mortality in diabetic
patients (2).
In the present study we investigated the plasma levels
of PC-Ag, PCA and TM in diabetic patients to evaluate the
endothelial cell damage and the status of natural
anticoagulants of plasma.
In our study the mean PC-Ag level was significantly
lower than that of the healthy control group (P < 0.001).
Our observation was well matched with Ceriello (5), and
Koert (8). By contrast, Takahashi (9), Saito (3), and
Garcia (4) found that PC-Ag levels of diabetics were
higher than that of the healthy control subjects.
In Takahashi’s study group, the number of diabetic
patients was very small (n = 17), and there were
significant differences between the mean age of diabetics
and healthy controls (45.3 ± 14.1 years and 24.5±5
years, respectively). Dolan (10) and Tait (11) found that
there were positive correlations between age and PC-Ag
and PCA. As a result, differences in PC-Ag levels may
depend on the age differences between both groups.
Dolan (10) showed that PCA levels were higher in ages
40-45 than ages 20-25 and the differences were
statistically significant. However, both investigators
declared that there were not any significant age
dependent differences in PC-Ag and PCA levels between
50-59 ages. On the other hand, they showed significant
age dependent differences in age groups of 35-39 and
40-44.
Saito et al. (3) found that the PC-Ag levels of the
diabetic patients were higher than that of the control
group, but the difference between these two groups was
not significant. They measured Gla-PC levels by using two
monoclonal antibodies with ELISA technique. The
difference between our results and Saito’s would be
caused by the usage of different antibodies. Garcia Frade
measured PC-Ag levels using electroimmunoassay (6).
The difference between our results and Garcia Frade’s
results may originate from the patient group containing
patients suffering from acute vascular diseases.
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Ceriello et al. (5) obtained lower PC-Ag and PCA levels
in patient groups with respect to their control group.
These investigators suggested that increased thrombin
production in diabetes mellitus causes enhanced activation
of protein C in the circulation and in turn enhanced
clearance from the blood. They also ascertained that the
low levels of PC-Ag and PCA showed negative correlation
with serum glucose levels (5).
When Koert et al. (8) compared PC-Ag levels of
diabetic children and adolescents with age matched
controls, they observed decreased levels of protein C
after a duration of 6 months. They suggested that this
decrement of the PC-Ag levels was caused by accelerated
turnover due to the hyperglycemia related cell damage.
We divided our patients into three further groups
according to their UAE levels: Group 1 (<30 mg/ml), 2
(30 -140 mg/ml) and 3 (>140 mg/ml). The mean PC-Ag
levels of Group 1, 2 and 3 were lower than that of the
control group (P < 0.01, P < 0.01 and P > 0.05). The
difference between the control group and Group 1 and
Group 2 was statistically significant. But the difference
between the control group and Group 3 was not
statistically significant. Few numbers of patients in Group
3 would be the cause of this statistical insignificance.
UAE reflects the diabetic microangiopathy.
determined low levels of PC-Ag even in
normoalbuminuric patients (Group 1). We maintain
low levels of PC-Ag are not the result of
microangiopathy, but the cause of it.

We
the
that
the

We found that PC-Ag levels of patients whose diabetic
age ≤10 years and >10 years were 67.24 ± 12.64% and
66.11 ± 15.34%, respectively. There was not a
statistically significant difference between these two
mean levels (P > 0.05). In contrast, both mean values
were lower than that of the control group’s mean value.
As a result, we could suggest that diabetes causes
decreased PC-Ag levels, but this change takes place in the
early phases of diabetes mellitus.
In our study, PC-Ag and PCA levels correlated with
serum cholesterol levels (r = + 0.403, P < 0.01, n = 46;
r = +0.402, P < 0.01, n = 42, respectively). Saito (3),
and Takahashi (12) showed that there was a correlation
between plasma PC-Ag and serum cholesterol level.
Cholesterol levels might affect Protein C and Protein S
metabolism.
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PC-Ag and PCA levels were found to be lower or
higher than that of the control group in different study
groups (2, 6, 13, 14 ). Different results obtained by
different investigations may depend on either differences
of the short term metabolic control of the diabetes, or
different techniques used in different studies. Plasma PCAg levels showed a positive correlation with serum
cholesterol levels and negative correlation with serum
glucose. In addition, PC-Ag levels of diabetic patients
having UAE levels of greater than 30 mg/ml were lower
than that of the control group. As a result of these
findings we may say that the PC- Ag levels are affected by
the short term metabolic control of the diabetic patients.
We obtained TM levels of 33.37 ± 13.43 ng/ml,
34.92 ± 9 ng/ml, and 40.33±4.64 ng/ml in Groups 1, 2
and 3, respectively. All these levels were higher than that
of the control group. Differences between the control
group and patient groups were statistically significant.
Mean TM levels of the Group 2 and 3 were higher than
that of Group 1, but the differences were not statistically
significant.
Iwassima (15) separated diabetic patients into three
groups according to the UAE level in their urine. Group 1,
2 and 3 consisted of patients whose UAE levels were: ≤
30 mg/ml, between 30-140 mg/ml, and >140 mg/ml
respectively. They demonstrated that there was no
statistically significant difference between the mean TM
levels of group 1 and the control group. However, TM
levels of Groups 2 and 3 were significantly higher than
that of the control and Group1. Moreover, TM levels of
Group 3 were also significantly higher than the level of
Group 2.

occurred as a result of diabetes mellitus may lead to these
elevated levels of TM.
Mean TM levels of patients whose diabetic were
longer than 10 years were higher than that of the
patients whose diabetic were shorter than 10 years (P <
0.001). The mean TM levels of both groups were higher
than that of the control group (P < 0.001, P < 0.001).
Iwashima (15) showed a positive correlation between
diabetic age and TM levels.
TM levels in diabetic patients were found to be higher
than that of the healthy controls. TM levels were found
increased especially in diabetic patients having UAE levels
greater than 30 mg/ml (15) and microangiopathy (16).
Beside renal disease, albuminuria reflects widespread
vascular injury in diabetes mellitus (1). There were no
correlations between TM and many metabolic products
found in the serum such as glucose, insulin, cholesterol,
triglyceride etc. These features make TM an ideal
endothelial marker. TM show endothelial damage rather
than endothelial function (16). As a result of our
observations, we may suggest that plasma TM levels
show the diabetes dependent microangiopathy
successfully.
Diabetes mellitus is characterized by vascular
complications. Coagulation abnormalties may be causally
related to and/or merely secondary to vascular diseases.
In our study, we show that vacular diseases and low
natural anticoagulant (PC-Ag) status together may cause
the thrombogenic tendencies in diabetes mellitus.
Corresponding author:
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Iwashima (15) determined that diabetic patients
having UAE and proteinuria had higher TM levels than
that of the control group. Endothelial injury which
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